Overview
The properly developed sibling of Melanotan II — selective for MC1R, delivered as a controlled-release implant by a physician, and approved for a rare photosensitivity disorder. It shows what the melanocortin pigmentation mechanism looks like when taken through real drug development.
FDA ApprovedFDA-approved (2019) and EMA-approved to increase pain-free light exposure in adults with erythropoietic protoporphyria
| Regulatory status | FDA-approved (2019) and EMA-approved to increase pain-free light exposure in adults with erythropoietic protoporphyria |
|---|---|
| Drug class | Selective MC1R agonist — alpha-MSH analog |
| Route | Subcutaneous implant (controlled release over ~2 months) |
| Half-life | Implant releases over approximately 2 months |
| Evidence rating |
5/5 Very strong
Evidence rating 5 out of 5: Very strong
Multiple phase 3 randomized trials plus regulatory approval in a major market. |
| Studied in | Randomized controlled trials in erythropoietic protoporphyria in the US and Europe; long-term post-authorisation safety registries. |
How it works
Selective MC1R agonism increases eumelanin production in the skin, providing photoprotection. In erythropoietic protoporphyria, this reduces the excruciating phototoxic pain that follows even brief light exposure.
Evidence base
Rated 5 of 5 — Very strong. Multiple phase 3 randomized trials plus regulatory approval in a major market.
- Randomized trials plus ongoing post-authorisation safety registries.
Benefits & potential uses
Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.
-
Increased pain-free light exposure in EPP Strong evidence
Randomized trials showed significant increases in time spent in direct sunlight without pain — transformative for a condition that otherwise confines patients indoors.
-
Improved quality of life Strong evidence
Validated quality-of-life measures improved substantially in trials and registries.
-
Receptor selectivity Strong evidence
MC1R selectivity avoids most of the MC4R and MC5R effects that make Melanotan II unpredictable.
-
Controlled physician-administered delivery Strong evidence
The implant removes dosing guesswork and self-injection risk entirely.
Risks, cons & cautions
Bars indicate seriousness: three = serious or common, two = moderate, one = minor.
-
Generalised skin darkening Minor
Expected and on-target, but cosmetically significant and unavoidable.
-
Implant site reactions Minor
Local reactions at the subcutaneous implant site are the most common adverse event.
-
Melanocytic lesion monitoring required Moderate evidence
Twice-yearly full-body skin examination is required by the label; it does not remove the need for sun protection.
-
Nausea, headache, fatigue Minor
Reported in trials, generally mild to moderate.
-
Very restricted indication and access Moderate evidence
Only for erythropoietic protoporphyria, administered in certified centres. It is not available or appropriate as a tanning product.
Who should avoid it
- Anyone without erythropoietic protoporphyria
- Hepatic impairment
- Pregnancy
If used under medical supervision, monitor
- Full-body skin examination twice yearly
- Liver function
- Implant site assessment
Commonly confused with
These mix-ups cause real harm — two products sold under one name, or two molecules whose effects run in opposite directions.
Afamelanotide is Melanotan I: selective, approved, physician-implanted, for a rare disease. Melanotan II is non-selective, unapproved, self-injected, and carries worldwide regulator warnings.
Compare side by sideRegulatory & legal status
Approved prescription implant, administered by certified healthcare professionals only.
Infographic
Where to read further
We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.
- PubMed — all published literature on Afamelanotide
- PubMed — randomized controlled trials only
- ClinicalTrials.gov — registered human trials
- DailyMed — official FDA prescribing information
Related peptides in Sexual Health & Melanocortin
Terms used on this page
- Melanocortin System
- The melanocortin system is the POMC-derived signalling network in which alpha-MSH and ACTH act on five receptors to control pigmentation, adrenal steroid output, appetite and energy balance.
- Subcutaneous Implant
- A subcutaneous implant is a solid depot placed under the skin by a minor procedure, releasing its drug slowly by diffusion or matrix erosion over months rather than hours.
- Melanocortin-1 Receptor (MC1R)
- MC1R is the G protein-coupled receptor on melanocytes that, when bound by alpha-MSH or ACTH, raises cyclic AMP and switches pigment synthesis from pheomelanin toward eumelanin.
- Agonist
- An agonist is a ligand that binds a receptor and stabilises its active conformation, producing a biological response rather than merely occupying the binding site.
- Receptor Selectivity
- Receptor selectivity is the degree to which a ligand acts on its intended receptor rather than related ones, expressed as the ratio between its potency at the target and at each off-target.
- MC3R vs MC4R
- MC3R and MC4R are the two central melanocortin receptors, with MC4R driving satiety and energy expenditure and MC3R tuning nutrient partitioning and the timing of puberty.
This page is educational information, not medical advice. It cannot account for your medical history, medications, or risk factors. Do not start, stop or change any treatment based on it. Speak to a qualified healthcare professional who knows your case.